Pre-made Erfonrilimab benchmark antibody ( Bispecific Single Domains (VH-VH'-CH), anti-CD274/PD-L1;CTLA4/CTLA-4 therapeutic antibody, Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1;CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-made Erfonrilimab benchmark antibody (Bispecific Single Domains (VH-VH’-CH), anti-CD274/PD-L1;CTLA4/CTLA-4 therapeutic antibody, Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1;CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
| Products Name (INN Index) | Pre-Made Erfonrilimab biosimilar, Bispecific Single Domains (VH-VH'-CH), Anti-CD274/PD-L1;CTLA4/CTLA-4 Antibody: Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1;CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 therapeutic ant |
|---|---|
| INN Name | Erfonrilimab |
| Target | CD274,CTLA4 |
| Format | Bispecific Single Domains (VH-VH'-CH) |
| Derivation | Bispecific antibody |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | na,na |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None;6rqm:B |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2020 |
| Year Recommended | NA |
| Companies | Alphamab |
| Conditions Approved | NA |
| Conditions Active | Non-small cell lung cancer,Triple-negative breast cancer,Esophageal carcinoma |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | CD274,CTLA4 |
| Package |
